Form 424B3 Cano Health, Inc.
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
PROSPECTUS SUPPLEMENT NO. 2
(to prospectus dated April 6, 2022)
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-257445
CANO HEALTH, INC.
Up to 328,758,279 Shares of Class A Common Stock
Up to 33,533,333 Shares of Class A Common Stock Issuable Upon Exercise of Warrants
Up to 10,533,333 Warrants to Purchase Common Stock
This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 6, 2022 (as supplemented or amended from time to time, the Prospectus), which forms part of our Registration Statement on Form S-1, as amended (File No. 333-257445). This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with the information contained or incorporated by reference in our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 18, 2022, which is set forth below.
This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.
Our Class A common stock is listed on The New York Stock Exchange under the symbol CANO. On May 17, 2022, the closing price of our Class A common stock was $5.61 per share.
Investing in our securities involves risks that are described in the Risk Factors section beginning on page 13 of the Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under this prospectus or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is May 19, 2022.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 16, 2022
Commission File Number: 001-39289
Cano Health, Inc.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of
incorporation or organization)
|9725 NW 117th Avenue, Miami, FL||33178|
|(Address of principal executive offices)||(Zip Code)|
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|Class A common stock, $0.0001 par value per share||CANO||The New York Stock Exchange|
|Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share||CANO/WS||The New York Stock Exchange|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders
On May 16, 2022, Cano Health, Inc. (the Company) held its 2022 annual meeting of stockholders (the Annual Meeting). There were 481,749,071 shares of the Companys Class A common stock and Class B common stock outstanding and entitled to vote at the Annual Meeting. 433,064,494 shares of the Companys Class A common stock and Class B common stock were represented in person or by proxy at the Annual Meeting, which constituted a quorum for the purpose of transacting business.
At the Annual Meeting, the Companys stockholders voted upon the following four matters:
1. The election of Dr. Lewis Gold, Barry S. Sternlicht and Solomon D. Trujillo as Class I directors, each to serve on the Companys Board of Directors for a three-year term and until their respective successors are duly elected and qualified.
2. The approval of a non-binding advisory resolution regarding the compensation of the Companys named executive officers.
3. The approval of a non-binding advisory resolution on whether an advisory vote on executive compensation should be held every one, two or three years.
4. The ratification of Ernst & Young LLP as the Companys independent registered public accounting firm for the year ending December 31, 2022.
The final voting results for each proposal are set forth below:
Proposal 1 - Election of Class I Directors
|Votes For||Withheld||Broker Non-Vote|
Dr. Lewis Gold
Barry S. Sternlicht
Solomon D. Trujillo
Each of the three director nominees listed above received the number of votes set forth opposite his name, constituting in each case a plurality of the votes cast at the Annual Meeting for the election of such director to serve on the Board of Directors for a term of three years and until his successor is duly elected and qualified.
Proposal 2 - Advisory Vote on Compensation of Named Executive Officers
The non-binding advisory resolution regarding the compensation of the Companys named executive officers was approved by the affirmative vote of a majority of the shares of common stock present or represented by proxy at the Annual Meeting.
Proposal 3 - Advisory Vote on Frequency of an Advisory Vote on Compensation of Named Executive Officers
|1 Year||2 Years||3 Years||Abstentions||Broker Non-Vote|
An advisory vote on executive compensation to be held annually received the highest number of votes of the shares of common stock present or represented by proxy at the Annual Meeting.
Proposal 4 - Ratification of Ernst & Young LLP as the Companys Independent Registered Public Accounting Firm for the Year Ending December 31, 2022
The ratification of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2022 was approved by the affirmative vote of a majority of the shares of common stock present or represented by proxy at the Annual Meeting.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|CANO HEALTH, INC.|
|Date: May 18, 2022||By:||/s/ Brian D. Koppy|
|Name:||Brian D. Koppy|
|Title:||Chief Financial Officer|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Raymond James Starts Cano Health (CANO) at Outperform
- Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
- Oasis Statement on Fujitec AGM
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!